Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAG | P20916 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 2/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25239763 | 0.89 | LMNA (0.41) | MAGCYP3A4MAPTCYP2C9CYP2C19 | |
| SCHEMBL22389306 | 0.89 | LMNA (0.41) | MAGCYP3A4MAPTCYP2C9CYP2C19 | |
| SCHEMBL19769332 | 0.81 | KMT2A (0.38) | CYP3A4MAPTCYP2C9CYP2C19KMT2A | |
| SCHEMBL22389399 | 0.78 | LMNA (0.37) | MAGCYP3A4MAPTCYP2C9CYP2C19 | |
| SCHEMBL19781227 | 0.78 | USP2 (0.42) | CYP2C9KMT2ALMNASMN1; SMN2MEN1 | |
| SCHEMBL19769319 | 0.78 | CYP3A4 (0.37) | CYP3A4MAPTCYP2C9CYP2C19KMT2A | |
| SCHEMBL26257040 | 0.74 | LMNA (0.48) | CYP3A4MAPTCYP2C9CYP2C19KMT2A | |
| SCHEMBL22389309 | 0.73 | KMT2A (0.35) | CYP3A4MAPTCYP2C9CYP2C19KMT2A | |
| SCHEMBL19769273 | 0.72 | CYP3A4 (0.36) | CYP3A4MAPTCYP2C9CYP2C19KMT2A | |
| SCHEMBL19769264 | 0.70 | CYP3A4 (0.42) | CYP3A4MAPTCYP2C9CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159458-A1 | SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE CONJUGATES | AM CHEMICALS LLC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20180016232-A1 | SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE CONJUGATES | AM CHEMICALS LLC (US) | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159458-A1 | SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE CONJUGATES | NCL, PAICS, RTCB | MAG 3685/4885CYP3A4 4155/4885MAPT 3747/4885 |
| US-20180016232-A1 | SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE CONJUGATES | NCL, PAICS, RTCB | MAG 3685/4885CYP3A4 4155/4885MAPT 3747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.